BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 23802849)

  • 1. Neurological events with tumour necrosis factor alpha inhibitors reported to the Food and Drug Administration Adverse Event Reporting System.
    Deepak P; Stobaugh DJ; Sherid M; Sifuentes H; Ehrenpreis ED
    Aliment Pharmacol Ther; 2013 Aug; 38(4):388-96. PubMed ID: 23802849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
    Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
    Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing the likelihood of new-onset inflammatory bowel disease following tumor necrosis factor-alpha inhibitor therapy for rheumatoid arthritis and juvenile rheumatoid arthritis.
    Krishnan A; Stobaugh DJ; Deepak P
    Rheumatol Int; 2015 Apr; 35(4):661-8. PubMed ID: 25228459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Melanoma and non-melanoma skin cancer in inflammatory bowel disease patients following tumor necrosis factor-α inhibitor monotherapy and in combination with thiopurines: analysis of the Food and Drug Administration Adverse Event Reporting System.
    McKenna MR; Stobaugh DJ; Deepak P
    J Gastrointestin Liver Dis; 2014 Sep; 23(3):267-71. PubMed ID: 25267954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ischaemic colitis in rheumatoid arthritis patients receiving tumour necrosis factor-α inhibitors: an analysis of reports to the US FDA Adverse Event Reporting System.
    Salk A; Stobaugh DJ; Deepak P; Ehrenpreis ED
    Drug Saf; 2013 May; 36(5):329-34. PubMed ID: 23580194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alleged isotretinoin-associated inflammatory bowel disease: disproportionate reporting by attorneys to the Food and Drug Administration Adverse Event Reporting System.
    Stobaugh DJ; Deepak P; Ehrenpreis ED
    J Am Acad Dermatol; 2013 Sep; 69(3):393-8. PubMed ID: 23683730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatosplenic T-cell lymphoma in patients receiving TNF-α inhibitor therapy: expanding the groups at risk.
    Parakkal D; Sifuentes H; Semer R; Ehrenpreis ED
    Eur J Gastroenterol Hepatol; 2011 Nov; 23(12):1150-6. PubMed ID: 21941193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maternal and foetal adverse events with tumour necrosis factor-alpha inhibitors in inflammatory bowel disease.
    Deepak P; Stobaugh DJ
    Aliment Pharmacol Ther; 2014 Nov; 40(9):1035-43. PubMed ID: 25164260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infectious complications of TNF-α inhibitor monotherapy versus combination therapy with immunomodulators in inflammatory bowel disease: analysis of the Food and Drug Administration Adverse Event Reporting System.
    Deepak P; Stobaugh DJ; Ehrenpreis ED
    J Gastrointestin Liver Dis; 2013 Sep; 22(3):269-76. PubMed ID: 24078983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Age-related trends in injection site reaction incidence induced by the tumor necrosis factor-α (TNF-α) inhibitors etanercept and adalimumab: the Food and Drug Administration adverse event reporting system, 2004-2015.
    Matsui T; Umetsu R; Kato Y; Hane Y; Sasaoka S; Motooka Y; Hatahira H; Abe J; Fukuda A; Naganuma M; Kinosada Y; Nakamura M
    Int J Med Sci; 2017; 14(2):102-109. PubMed ID: 28260984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Demyelinizing neurological disease after treatment with tumor necrosis factor alpha-inhibiting agents in a rheumatological outpatient clinic: description of six cases.
    Theibich A; Dreyer L; Magyari M; Locht H
    Clin Rheumatol; 2014 May; 33(5):719-23. PubMed ID: 24202614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drugs associated with adverse events in children and adolescents.
    Lee WJ; Lee TA; Pickard AS; Caskey RN; Schumock GT
    Pharmacotherapy; 2014 Sep; 34(9):918-26. PubMed ID: 24990656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients.
    Gerloni V; Pontikaki I; Gattinara M; Fantini F
    Ann Rheum Dis; 2008 Aug; 67(8):1145-52. PubMed ID: 17981916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arterial and venous thromboembolic events during anti-TNF therapy: a study of 85 spontaneous reports in the period 2000-2006.
    Petitpain N; Gambier N; Wahl D; Chary-Valckenaere I; Loeuille D; Gillet P;
    Biomed Mater Eng; 2009; 19(4-5):355-64. PubMed ID: 20042802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases.
    Coté TR; Mohan AK; Polder JA; Walton MK; Braun MM
    J Am Acad Dermatol; 2005 Sep; 53(3):407-15. PubMed ID: 16112345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Neurological adverse events under anti-TNF alpha therapy].
    Cohen M; Baldin B; Thomas P; Lebrun C
    Rev Neurol (Paris); 2012 Jan; 168(1):33-9. PubMed ID: 22098827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents.
    Mohan N; Edwards ET; Cupps TR; Slifman N; Lee JH; Siegel JN; Braun MM
    J Rheumatol; 2004 Oct; 31(10):1955-8. PubMed ID: 15468359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ischemic colitis with type I interferons used in the treatment of hepatitis C and multiple sclerosis: an evaluation from the food and drug administration adverse event reporting system and review of the literature.
    Salk A; Stobaugh DJ; Deepak P; Ehrenpreis ED
    Ann Pharmacother; 2013 Apr; 47(4):537-42. PubMed ID: 23535814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pediatric drug surveillance and the Food and Drug Administration's adverse event reporting system: an overview of reports, 2003-2007.
    Johann-Liang R; Wyeth J; Chen M; Cope JU
    Pharmacoepidemiol Drug Saf; 2009 Jan; 18(1):24-7. PubMed ID: 19009550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topical bovine thrombin: a 21-year review of topical bovine thrombin spontaneous case safety reports submitted to FDA's Adverse Event Reporting System.
    Clark JA; Humphries JE; Crean S; Reynolds MW
    Pharmacoepidemiol Drug Saf; 2010 Feb; 19(2):107-14. PubMed ID: 20014051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.